Latest news with #PMMA
Daily Mirror
20-05-2025
- Health
- Daily Mirror
'I was convinced to have a penis enlargement - then I almost lost my manhood'
A man who said he became convinced by online adverts for penis enlargement suddenly faced life-threatening health issues - 'Jorge' faced the possibility he could lose his penis A man was left fighting for his life because of how much he had changed his penis. The unfortunate gent, named Jorge, needed two surgeries to reconstruct his penis following attempts to alter it for cosmetic purposes. Jorge, not his real name, said he had becom e 'convinced' by dodgy advertisements that promised they could enlarge his penis. The Brazilian local travelled to the city of São Paulo in 2015 to have two lots of fillers put in to try and enhance his manhood. He explained: "In mid-2005, I was convinced by advertisements published in newspapers and magazines that promised penis enlargement." Speaking to BBC Brasil, he added: 'I decided to travel to São Paulo and had PMMA applied in a well-hidden clinic. I didn't even know if the professional who treated me was a doctor.' He liked the results, but was left wanting more ten years later. He underwent a second injection in his home region, Brazil 's Federal District. Again pleased with his altered appendage, Jorge went back for more three years later. He saw two doctors and one of them spoke to him about applying some filler to his scrotum and even another extensive procedure. Jorge says this is when his 'big drama' began. Two years after the procedure, he began to suffer recurring inflammation in his pelvis. When this occurred, his scrotum would double in size. "The doctors had to apply [anti-inflammatory drugs] directly into my scrotum," he recalled, describing the painful time. Eventually, wounds began to appear. "It was as if my body wanted to expel that PMMA somehow," Jorge said, referring to the type of filler, Polymethylmethacrylate (PMMA) used. It soon became clear he might soon lose his penis as the situation worsened. Jorge needed to have the PMMA filler removed, while the areas of his sexual organ affected by the problem needed reconstructing. The first procedure, on his scrotum, took place last year. Then, Jorge had a second operationin April this year. "It was possible to heal the wounds and remove a good part of the PMMA," he said, adding he has been able to recover some self-esteem. He urged others to 'avoid fantastical propaganda' and seek 'reliable information' before going ahead with any procedure on their penis. He added people should try not to have 'vanity' and act like an 'imbecile'. Doctors said problems experienced by Jorge have become more common recently. Specialist Dr Flávio Rezende said men were hit with dodgy adds for years over strange ways to enlarge their penis. "There were advertisements for massage creams, vacuum pumps,' the doc, a member of the Brazilian Society of Plastic Surgery, said. 'Throughout their lives, many individuals had no real possibility of treatment.'
Business Wire
07-05-2025
- Business
- Business Wire
Trinseo Reports First Quarter 2025 Financial Results and Provides Second Quarter Outlook
WAYNE, Pa.--(BUSINESS WIRE)--Trinseo (NYSE: TSE): Three Months Ended March 31, $millions, except per share data 2025 2024 Net Sales $ 785 $ 904 Net Loss (79 ) (76 ) Diluted EPS ($) (2.22 ) (2.14 ) Adjusted Net Loss* (49 ) (69 ) Adjusted EPS ($)* (1.37 ) (1.94 ) EBITDA* 30 38 Adjusted EBITDA* 65 45 Expand *For a reconciliation of EBITDA, Adjusted EBITDA, and Adjusted Net Loss, all of which are non-GAAP measures, to Net Loss, as well as a reconciliation of Free Cash Flow and Adjusted EPS, see Notes 2 and 3 to the financial statements included below. Trinseo (NYSE: TSE), a specialty material solutions provider, today reported its first quarter 2025 financial results. Net sales of $785 million in the first quarter decreased 13% versus prior year from lower sales volume across all business segments due to continued end market demand weakness and intentional reductions of low-margin sales. Higher prices, primarily from the pass-through of higher raw material costs and improved product mix, led to a 2% increase which was offset by a 2% decrease from currency. First quarter net loss of $79 million was $3 million higher than prior year primarily due to higher interest expense and a slightly higher provision for income taxes. Adjusted EBITDA of $65 million was $20 million above prior year driven by $26 million of polycarbonate technology licensing income as well as savings from the previously announced restructuring actions. These were partially offset by lower volumes as well as lower income from Americas Styrenics. Commenting on the Company's first quarter performance, Frank Bozich, President and Chief Executive Officer of Trinseo, said, 'Core business results in the first quarter were in line with expectations, and sequentially higher due to prior quarter customer destocking and seasonality. Despite persistent market weakness, the first quarter was Trinseo's 7 th consecutive quarter of year-over-year Adjusted EBITDA improvement driven by the various management actions we took early in this industry downturn.' First Quarter Results and Commentary by Business Segment Engineered Materials net sales of $278 million for the quarter were 2% below prior year as lower sales volume was partially offset by higher pricing. Adjusted EBITDA of $26 million was $16 million above prior year, reflecting higher margins from moderating input costs. Sales volume growth in consumer electronics applications and from our geographic expansion initiatives for PMMA were offset by lower market demand in automotive and building and construction. Latex Binders net sales of $209 million for the quarter decreased 13% versus prior year from lower volumes, primarily in paper applications in Asia and Europe, which were partially offset by higher price. Adjusted EBITDA of $24 million was $2 million below prior year due to lower volume. Net sales to CASE applications accounted for 15% of total segment net sales with volume increasing 3% over prior year in a flat market environment. Polymer Solutions net sales of $298 million for the quarter decreased 22% versus prior year due to lower sales volume, which was primarily the result of intentionally reducing low-margin polystyrene sales. Adjusted EBITDA of $44 million was $15 million above prior year, as lower volumes and margins were more than offset by fixed cost reductions and $26 million of polycarbonate technology licensing income. Americas Styrenics Adjusted EBITDA of negative $2 million for the quarter was $8 million below prior year mainly driven by an unfavorable timing impact. Second Quarter 2025 Outlook Second quarter 2025 net loss of $61 million to $46 million Second quarter 2025 Adjusted EBITDA of $55 million to $70 million Second quarter 2025 Free Cash Flow approximately breakeven and includes $21 million from the polycarbonate technology license income collected in the second quarter We expect the direct impact from current tariffs to be limited, as we generally manufacture products and procure raw materials in the regions where our products are sold. However, the high level of macroeconomic uncertainty that currently exists limits our ability to assess future end-market demand. Therefore, we are withdrawing all full-year guidance previously furnished in connection with our recent debt refinancing and will focus only on second quarter guidance. Commenting on the second quarter outlook, Bozich said, 'We anticipate Adjusted EBITDA of $55 million to $70 million in Q2 with seasonally higher volumes, lower costs in Engineered Materials, and improved AmSty performance offsetting the first quarter polycarbonate technology license income. I am extremely proud of the agility and resourcefulness demonstrated by all of our employees as we navigate this challenging market environment. Conference Call and Webcast Information Trinseo will host a conference call to discuss its first quarter 2025 financial results on Thursday, May 8, 2025 at 10 a.m. Eastern Time. Commenting on results will be Frank Bozich, President and Chief Executive Officer, David Stasse, Executive Vice President and Chief Financial Officer, and Bee van Kessel, Senior Vice President, Corporate Finance and Investor Relations. For those interested in asking questions during the Q&A session, please register using the following link: Conference Call Registration For those interested in listening only, please register for the webcast using the following link: Webcast Registration After registering for the conference call, you will receive a confirmation email with a meeting invitation and information for entry. Registration is open through the live call, but it is advised that you register in advance to ensure you are connected for the full call. Trinseo has posted its first quarter 2025 financial results on the Company's Investor Relations website. The presentation slides will also be made available in the webcast player prior to the conference call. The Company will also furnish copies of the financial results press release and presentation slides to investors by means of a Form 8-K filing with the U.S. Securities and Exchange Commission. A replay of the conference call and transcript will be archived on the Company's Investor Relations website shortly following the conference call. The replay will be available until May 8, 2026. About Trinseo Trinseo (NYSE: TSE), a specialty material solutions provider, partners with companies to bring ideas to life in an imaginative, smart and sustainably focused manner by combining its premier expertise, forward-looking innovations and best-in-class materials to unlock value for companies and consumers. From design to manufacturing, Trinseo taps into decades of experience in diverse material solutions to address customers' unique challenges in a wide range of industries, including building and construction, consumer goods, medical and mobility. Trinseo's employees bring endless creativity to reimagining the possibilities with clients all over the world from the company's locations in North America, Europe and Asia Pacific. Trinseo reported net sales of approximately $3.5 billion in 2024. Discover more by visiting and connecting with Trinseo on LinkedIn, Twitter, Facebook. Use of non-GAAP measures In addition to using standard measures of performance and liquidity that are recognized in accordance with accounting principles generally accepted in the United States of America ('GAAP'), we use additional measures of income excluding certain GAAP items ('non-GAAP measures'), such as Adjusted Net Income, EBITDA, Adjusted EBITDA and Adjusted EPS and measures of liquidity excluding certain GAAP items, such as Free Cash Flow. We believe these measures are useful for investors and management in evaluating business trends and performance each period. These measures are also used to manage our business and assess current period profitability, as well as to provide an appropriate basis to evaluate the effectiveness of our pricing strategies. Such measures are not recognized in accordance with GAAP and should not be viewed as an alternative to GAAP measures of performance or liquidity, as applicable. The definitions of each of these measures, further discussion of usefulness, and reconciliations of non-GAAP measures to GAAP measures are provided in the Notes to Condensed Consolidated Financial Information presented herein. Cautionary Note on Forward-Looking Statements This press release may contain forward-looking statements including, without limitation, statements concerning plans, objectives, goals, projections, forecasts, strategies, future events or performance, and underlying assumptions and other statements, which are not statements of historical facts or guarantees or assurances of future performance. Forward-looking statements may be identified by the use of words like 'expect,' 'anticipate,' 'believe,' 'intend,' 'forecast,' 'estimate,' 'see,' 'outlook,' 'will,' 'may,' 'might,' 'potential,' 'likely,' 'target,' 'plan,' 'contemplate,' 'seek,' 'attempt,' 'should,' 'could,' 'would,' or expressions of similar meaning. Forward-looking statements reflect management's evaluation of information currently available and are based on our current expectations and assumptions regarding our business, the economy, our current indebtedness, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Factors that might cause future results to differ from those expressed by the forward-looking statements include, but are not limited to, conditions in the global economy and capital markets, including recessionary conditions and the impact of tariffs on global trade relations; our ability to successfully generate cost savings through restructuring and cost reduction initiatives; our ability to successfully execute our business and transformation strategy; increased costs or disruption in the supply of raw materials; deterioration of our credit profile limiting our access to commercial credit; increased energy costs; the timing of, and our ability to complete, a sale of our interest in Americas Styrenics; compliance with laws and regulations impacting our business; any disruptions in production at our chemical manufacturing facilities, including those resulting from accidental spills or discharges; our current and future levels of indebtedness and our ability to service, repay or refinance our indebtedness; our ability to meet the covenants under our existing indebtedness; our ability to generate cash flows from operations and achieve our forecasted cash flows; and those discussed in our Annual Report on Form 10-K, under Part I, Item 1A —"Risk Factors" and elsewhere in our other reports, filings and furnishings made with the U.S. Securities and Exchange Commission from time to time. As a result of these or other factors, our actual results, performance or achievements may differ materially from those contemplated by the forward-looking statements. Therefore, we caution you against relying on any of these forward-looking statements. The forward-looking statements included in this press release are made only as of the date hereof. We undertake no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as otherwise required by law. TRINSEO PLC Condensed Consolidated Balance Sheets (In millions) (Unaudited) March 31, 2025 2024 Assets Cash and cash equivalents $ 126.1 $ 209.8 Accounts receivable, net of allowance 470.5 379.9 Inventories 383.7 347.2 Other current assets 55.7 51.3 Investments in unconsolidated affiliate 220.8 222.6 Property, plant, equipment, goodwill, and other intangible assets, net 1,218.6 1,234.5 Right-of-use assets - operating, net 62.6 63.9 Other long-term assets 117.0 134.9 Total assets $ 2,655.0 $ 2,644.1 Liabilities and shareholders' equity Current liabilities 689.3 720.9 Long-term debt, net of unamortized deferred financing fees 2,305.1 2,200.7 Noncurrent lease liabilities - operating 52.7 53.3 Other noncurrent obligations 287.1 289.1 Shareholders' equity (deficit) (679.2 ) (619.9 ) Total liabilities and shareholders' equity (deficit) $ 2,655.0 $ 2,644.1 Expand TRINSEO PLC Condensed Consolidated Statements of Cash Flows (In millions) (Unaudited) Three Months Ended March 31, 2025 2024 Cash flows from operating activities Cash used in operating activities $ (110.2 ) $ (66.2 ) Cash flows from investing activities Capital expenditures (8.7 ) (15.7 ) Proceeds from the sale of businesses and other assets — 4.7 Cash used in investing activities (8.7 ) (11.0 ) Cash flows from financing activities Deferred financing fees (19.8 ) 0.4 Short-term borrowings, net (1.8 ) (3.7 ) Dividends paid (0.5 ) (0.6 ) Acquisition-related contingent consideration payment — (0.7 ) Net proceeds from issuance of 2028 Refinance Term Loans 115.0 — Repurchases and repayments of long-term debt (5.1 ) (4.6 ) Repayments of 2025 Senior Notes (115.0 ) — Proceeds from Accounts Receivable Securitization Facility 70.0 30.0 Repayments of Accounts Receivable Securitization Facility (10.0 ) (30.0 ) Cash provided by (used in) financing activities 32.8 (9.2 ) Effect of exchange rates on cash 2.5 (3.2 ) Net change in cash, cash equivalents, and restricted cash (83.6 ) (89.6 ) Cash, cash equivalents, and restricted cash—beginning of period 211.9 261.1 Cash, cash equivalents, and restricted cash—end of period $ 128.3 $ 171.5 Less: Restricted cash 2.2 5.1 Cash and cash equivalents—end of period $ 126.1 $ 166.4 Expand TRINSEO PLC Notes to Condensed Consolidated Financial Information (Unaudited) Note 1: Net Sales by Segment Three Months Ended March 31, (In millions) 2025 2024 Engineered Materials $ 277.3 $ 282.5 Latex Binders 209.3 241.5 Polymer Solutions 298.2 380.0 Americas Styrenics* — — Total Net Sales $ 784.8 $ 904.0 Expand * The results of this segment are comprised entirely of earnings from Americas Styrenics, our 50%-owned equity method investment. As such, we do not separately report net sales of Americas Styrenics within our condensed consolidated statements of operations. Note 2: Reconciliation of Non-GAAP Performance Measures to Net Income EBITDA is a non-GAAP financial performance measure, which is defined as income from continuing operations before interest expense, net; income tax provision; depreciation and amortization expense. We refer to EBITDA in making operating decisions because we believe it provides our management as well as our investors with meaningful information regarding the Company's operational performance. We believe the use of EBITDA as a metric assists our board of directors, management and investors in comparing our operating performance on a consistent basis. We also present Adjusted EBITDA as a non-GAAP financial performance measure, which we define as income from continuing operations before interest expense, net; income tax provision; depreciation and amortization expense; loss on extinguishment of long-term debt; asset impairment charges; gains or losses on the dispositions of businesses and assets; restructuring charges; acquisition related costs and benefits, and other items. In doing so, we are providing management, investors, and credit rating agencies with an indicator of our ongoing performance and business trends, removing the impact of transactions and events that we would not consider a part of our core operations. Lastly, we present Adjusted Net Income (Loss) and Adjusted EPS as additional performance measures. Adjusted Net Income (Loss) is calculated as Adjusted EBITDA (defined beginning with net income from continuing operations, above), less interest expense, less the provision for income taxes and depreciation and amortization, tax affected for various discrete items, as appropriate. Adjusted EPS is calculated as Adjusted Net Income (Loss) per weighted average diluted shares outstanding for a given period. We believe that Adjusted Net Income (Loss) and Adjusted EPS provide transparent and useful information to management, investors, analysts and other stakeholders in evaluating and assessing our operating results from period-to-period after removing the impact of certain transactions and activities that affect comparability and that are not considered part of our core operations. There are limitations to using the financial performance measures noted above. These performance measures are not intended to represent net income or other measures of financial performance. As such, they should not be used as alternatives to net income as indicators of operating performance. Other companies in our industry may define these performance measures differently than we do. As a result, it may be difficult to use these or similarly named financial measures that other companies may use, to compare the performance of those companies to our performance. We compensate for these limitations by providing reconciliations of these performance measures to our net income, which is determined in accordance with GAAP. March 31, (In millions, except per share data) 2025 2024 Net loss $ (79.0 ) $ (75.5 ) Interest expense, net 66.6 63.0 Provision for income taxes 6.6 5.4 Depreciation and amortization (a) 36.0 45.0 EBITDA $ 30.2 $ 37.9 Loss on financing transactions (b) 24.9 — Selling, general, and administrative expenses, Other expense (income), net Net gain on disposition of businesses and assets — (3.6 ) Selling, general, and administrative expenses Restructuring and other charges (c) 7.4 9.4 Selling, general, and administrative expenses Other items (d) 2.3 1.3 Selling, general, and administrative expenses Adjusted EBITDA $ 64.8 $ 45.0 Adjusted EBITDA to Adjusted Net Loss: Adjusted EBITDA 64.8 45.0 Interest expense, net 66.6 63.0 Provision for income taxes - Adjusted (e) 1.2 4.2 Depreciation and amortization - Adjusted (f) 45.5 46.3 Adjusted Net Loss $ (48.5 ) $ (68.5 ) Adjusted EPS $ (1.37 ) $ (1.94 ) Adjusted EBITDA by Segment: Engineered Materials $ 25.7 $ 10.4 Latex Binders 24.5 25.7 Polymer Solutions 44.5 29.1 Americas Styrenics (1.8 ) 6.2 Corporate Unallocated (28.1 ) (26.4 ) Adjusted EBITDA $ 64.8 $ 45.0 Expand _________________________ (a) During the three months ended March 31, 2025, an $8.1 million benefit was recognized due to a change in cost estimate related to the Boehlen, Germany asset retirement obligation as the Company was able to realize efficiencies during decommissioning. (b) Amounts for the three months ended March 31, 2024 primarily relate to fees incurred in conjunction with Company's debt refinancing transaction that did not meet the criteria for deferred financing charges. (c) Restructuring and other charges for the 2025 and 2024 periods primarily relate to employee termination benefits, contract termination costs as well as decommissioning and other charges incurred in connection with the Company's restructuring plans. (d) Other items for the 2025 period primarily relate to fees incurred in conjunction with certain of the Company's strategic initiatives, including the potential divestiture of our styrenics business. Other items for the 2024 period primarily relate to fees incurred in conjunction with certain of the Company's strategic initiatives, as well as costs related to our transition to a new enterprise resource planning system. (e) Adjusted to remove the tax impact of the items noted within the table above. The income tax expense (benefit) related to these items was determined utilizing either (1) the estimated annual effective tax rate on our ordinary income based upon our forecasted ordinary income for the full year or, (2) for items treated discretely for tax purposes we utilized the applicable rates in the taxing jurisdictions in which these adjustments occurred. (f) Amounts for the three months ended March 31, 2025 and 2024 excludes accelerated depreciation of $9.4 million and $1.3 million, respectively. The 2025 and 2024 period charges are primarily related to the shortening of the useful life of certain assets related to the 2024 restructuring plan. Expand For the same reasons discussed above, we are providing the following reconciliation of forecasted net loss to forecasted Adjusted EBITDA, Adjusted Net Loss and Adjusted EPS for the three months ended June 30, 2025. See 'Note on Forward-Looking Statements' above for a discussion of the limitations of these forecasts. Totals may not sum due to rounding. (g) Reconciling items to Adjusted EBITDA and Adjusted Net Income (Loss) are not typically forecasted by the Company based on their nature as being primarily driven by transactions that are not part of the core operations of the business and, as a result, cannot be estimated without unreasonable cost or uncertainty. As such, for the forecasted second quarter ended June 30, 2025, we have not included estimates for these items. (h) Weighted average shares presented for the purpose of forecasting EPS and Adjusted EPS assume that the Company will be in a net loss position for second quarter 2025, and therefore excludes the impact of potentially dilutive shares, as the inclusion of said shares would have an anti-dilutive effect. Further, the weighted average shares presented do not forecast significant future share transactions or events, such as repurchases, significant share-based compensation award grants, and changes in the Company's share price. These are all factors which could have a significant impact on the calculation of EPS and Adjusted EPS during actual future periods. Expand Note 3: Reconciliation of Non-GAAP Liquidity Measures to Cash from Operations The Company uses certain measures, such as Free Cash Flow as non-GAAP measures, to evaluate and discuss its liquidity position and results. Free Cash Flow is defined as cash from operating activities, less capital expenditures. We believe that Free Cash Flow provides an indicator of the Company's ongoing ability to generate cash through core operations, as it excludes the cash impacts of various financing transactions as well as cash flows from business combinations that are not considered organic in nature. We also believe that Free Cash Flow provides management and investors with useful analytical indicators of our ability to service our indebtedness, pay dividends (when declared), and meet our ongoing cash obligations. Free Cash Flow is not intended to represent cash flows from operations as defined by GAAP, and therefore, should not be used as alternatives for that measure. Other companies in our industry may define Free Cash Flow differently than we do. As a result, it may be difficult to use this or similarly named financial measures that other companies may use, to compare the liquidity and cash generation of those companies to our own. The Company compensates for these limitations by providing the following detail, which is determined in accordance with GAAP. Free Cash Flow
Yahoo
18-04-2025
- Business
- Yahoo
Digital Denture (Tubes, Tips, Restractors, Cannulae) Market by Usability (Disposable, Reusable), Application (General Surgery, Neurosurgery, Orthopedic, Cardiovascular, Dental)
Technological advancements like 3D printing and CAD/CAM are revolutionizing denture fabrication, enhancing precision and reducing dental visits. The complete denture segment is predicted to soar, driven by increased awareness of digital denture benefits. Materials like PMMA and resin offer customization and longevity. Fixed denture usage is rising for stability, and hospitals and clinics are rapidly adopting digital solutions. North America leads growth, fueled by an aging population's demand for superior dental options. Major players include DENTSPLY SIRONA Inc., Straumann Group, and Planmeca Group. This comprehensive report provides critical insights into market drivers, challenges, and competitive landscapes. Digital Denture Market Dublin, April 18, 2025 (GLOBE NEWSWIRE) -- The "Digital Denture Market by Type (Tubes, Tips, Restractors, Cannulae), Usability (Disposable, Reusable), Application (General Surgery, Neurosurgery, Orthopedic, Cardiovascular, Dental), End User, and Region - Global Forecast to 2029" has been added to offering. The global digital denture market is expected to escalate to USD 2.16 billion by 2029, from USD 1.42 billion in 2024, marking a CAGR of 8.7% during the forecast period of 2024-2029. This growth is attributed to continuous advancements in medical device technologies, particularly in the realm of digital dentistry. The integration of 3D printing and Computer-Aided Design/Manufacturing (CAD/CAM) technologies is profoundly transforming denture fabrication by enhancing precision, speed, and customization, thereby improving the overall fit and patient satisfaction. The complete denture segment is projected to witness the highest CAGR within the digital denture market. The growing awareness of digital dentures' benefits, such as improved comfort, expedited turnaround times, and enhanced precision, continues to drive adoption among both dental professionals and their patients. Increasing instances of edentulism, rooted in periodontal diseases and aging, amplify the demand for innovative denture solutions. Despite advances in preventative care, tooth loss remains prevalent, fueling market expansion. Regarding material choice, the resins segment is poised for the highest CAGR in digital dentures. Advanced materials like Polymethyl Methacrylate (PMMA), resin, and ceramics augmented by technological advances in 3D printing and CAD/CAM allow for the creation of customized, durable dentures that enhance user comfort. The efficiency of resin materials, quickly printed or milled with precision, addresses the demand for both speed and cost-effectiveness, propelling market growth. The fixed denture segment is expected to grow rapidly within the digital denture market. There is a noticeable shift towards fixed dentures due to their stability and aesthetic advantages. Globally, the aging population, accompanied by an increase in tooth loss, necessitates long-term dental care solutions. Moreover, fixed dentures reduce jawbone loss risk, offering superior functionality compared to removable options. Hospitals and clinics dominate the end-user segment, promising the highest CAGR in the digital denture market. The adoption of digital dentures in medical establishments, especially in geriatric and prosthetic dentistry departments, underscores the drive for efficiency and elevated patient satisfaction levels. Independent clinics and chain dental networks are incorporating digital denture technologies, striving to remain competitive and cater to evolving patient expectations for precise dental care. North America leads in expected growth with the highest CAGR in digital dentures during the forecast period. The region's increasing elderly demographics, mainly in the U.S. and Canada, drive the demand for dentures that offer an improved fit and aesthetics. As digital dentures gain traction for their natural appearance and comfort, awareness and demand burgeon, spurring clinics to adopt these modern solutions. Key market participants include: Major players in the market include DENTSPLY SIRONA Inc., Straumann Group, Planmeca Group, Modern Dental Group, Medit Corp., Stratasys Ltd., Ivoclar Vivadent AG, 3D Systems Corporation, Desktop Metal, and Amann Girrbach AG, among many others. By Company Type: Tier 1 - 50%, Tier 2 - 35%, Tier 3 - 15%. By Designation: C-level - 35%, Director Level - 40%, Others - 25%. By Region: North America - 35%, Europe - 20%, Asia Pacific - 10%, Latin America - 20%, Middle East & Africa - 15%. Insights include: Key drivers such as technology advancements, oral health disorder prevalence, and the surge in cosmetic dental procedures. Restraints like high implementation costs and reimbursement issues. Opportunities within dental service organizations and emerging markets. Challenges including a shortage of trained dental practitioners. Market penetration, product innovation, and diversification insights. Competitive assessment and in-depth analysis of major market players. Key Attributes: Report Attribute Details No. of Pages 282 Forecast Period 2024 - 2029 Estimated Market Value (USD) in 2024 $1.42 Billion Forecasted Market Value (USD) by 2029 $2.16 Billion Compound Annual Growth Rate 8.7% Regions Covered Global Market Dynamics Drivers Growing Focus on Technological Innovation for Dental Materials Increasing Prevalence of Oral Health Disorders Rising Geriatric Population and Subsequent Increase in Edentulism Growing Demand for Advanced Cosmetic Dental Procedures Expanding Market for Dental Tourism Challenges Shortage of Skilled Dental Practitioners Industry Trends Growing Preference for Minimally Invasive Dental Procedures Integration of Digital Workflow Increasing Focus on Product Development Dental Insurance in US Opportunities Impact of Dsos on Dental Industry Investments in Cad/Cam Technologies by Dentist Laboratories Growth Potential of Emerging Economies Case Studies Case Study 1: Product Launches and Technology Assessment Related to Antimicrobial Agents & Coating Substances for Dental Implants Case Study 2: Customized Study for Middle East & Africa Digital Dentures Market Case Study 3: Customized Study for Latin America Digital Dentures & Consumables Market Company Profiles 3Shape A/S Dentsply Sirona Institut Straumann AG Desktop Metal, Inc. Modern Dental Group Limited Planmeca Oy Stratasys 3D Systems, Inc. Ivoclar Vivadent Intraoral Scanners and Dental Software Amann Girrbach AG Mitsui Chemicals Group Bego GmbH & Co. KG Neoss AG Dws Srl Asiga Midmark Corporation Carima Co. Ltd. Shandong Huge Dental Material Corporation Jiangsu Weiyun Artificial Intelligence Co. Ltd. (AI Smile) Planet Dds Gc International AG Durr Dental SE Blz Dental Imesicore GmbH For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Digital Denture Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
